Purpose. We hypothesize that patients with type 1 diabetes (T1D) may have abnormal retinal vascular responses before diabetic retinopathy (DR) is clinically evident. Optical coherence tomography angiography (OCTA) was used to dynamically assess the retinal microvasculature of diabetic patients with no clinically visible retinopathy.

Methods. Controlled nonrandomized interventional study. The studied population included 48 eyes of 24 T1D patients and 24 demographically similar healthy volunteers. A commercial OCTA device (AngioVue) was used, and two tests were applied: (1) the hypoxia challenge test (HCT) and (2) the handgrip test to induce a vasodilatory or vasoconstrictive response, respectively. The HCT is a standardized test that creates a mild hypoxic environment equivalent to a flight cabin. The handgrip test (i.e., isometric exercise) induces a sympathetic autonomic response. Changes in the parafoveal superficial and deep capillary plexuses in both tests were compared in each group. Systemic cardiovascular responses were also comparatively evaluated.

Results. In the control cohort, the vessel density of the median parafoveal superficial and deep plexuses increased during hypoxia ($F_{1,23}=15.69$, $P<0.001$ and $F_{1,23}=16.26$, $P<0.001$, respectively). In the T1D group, this physiological response was not observed in either the superficial or the deep retinal plexuses. Isometric exercise elicited a significant decrease in vessel density in both superficial and deep plexuses in the control group ($F_{1,23}=27.37$, $P<0.0001$ and $F_{1,23}=27.90$, $P<0.0001$, respectively). In the T1D group, this response was noted only in the deep plexus ($F_{1,23}=11.04$, $P<0.01$).

Conclusions. Our work suggests there is an early impairment of the physiological retinal vascular response in patients with T1D without clinical diabetic retinopathy.

Keywords: optical coherence tomography angiography, handgrip test, hypoxia challenge test, retinal vascular reactivity, subclinical retinopathy
with unprecedented resolution. It does so by detecting motion contrast produced by moving red blood cells in retinal vessels over sequential B-scans without any need for a contrast injection. By examining serial images over time, the generated final image clearly defines retinal vascular plexuses.21

Recently, a few studies using OCTA have been reporting structural quantitative changes (i.e., reduced vessel density and increased foveal avascular area) in patients with diabetes before clinically evident DR.13−20 However, little is known about the possibility of using OCTA to evaluate individual functional retinal vascular changes. Our group recently published a safe, reproducible and inexpensive protocol to assess retinal microvasculature reactivity in healthy subjects, detailing how OCTA technology is able to detect retinal vasodilation and vasoconstriction in response to two physiological conditions—mild hypoxia and isometric exercise, respectively.21

We hypothesize that patients with diabetes may have altered physiological retinal vascular responses early in the natural history of the disease. Therefore, OCTA was used to dynamically study the retinal microvasculature of diabetic patients with no visible signs of retinopathy, thus contributing to the understanding of the earliest processes of DR development.

**MATERIAL AND METHODS**

**Ethics and Informed Consent**

Our research protocol follows the tenets of the Declaration of Helsinki22 and was submitted and approved by the Ethics Committee of Lisbon Academic Medical Center. Written, informed consent was obtained from all participants after detailing the aims, procedures and risks of the study. Two standardized tests were applied: (1) the hypoxia challenge test (HCT)23 and (2) the handgrip test.24 As recommended by the Ethics Committee, to minimize ethical concerns regarding the HCT, patients and volunteers recruited must have had the intention to fly in the future. All safety recommendations regarding the handgrip test were also followed and the test was discontinued if necessary.24 Medical confidentiality was assured. At any time, subjects could anonymously withdraw from the study. The study protocol has been registered in the ISRCTN clinical studies online platform with the number 98388473, available online at http://www.isrctn.com/ISRCTN98388473.

**Study Design, Participants, and Inclusion/Exclusion Criteria**

A controlled nonrandomized interventional study was conducted, including one group of patients with type 1 diabetes (T1D) without clinical signs of DR, and a demographically similar control group of healthy subjects.

Patients with T1D were recruited from an adult diabetes outpatient clinic, and a demographically (age and sex) similar sample of healthy volunteers was selected as a control group. An anonymous questionnaire was carried out, including the following questions: age, sex, smoking-pack years, known diseases and current chronic medication, previous intraocular surgery or trauma, symptoms during previous flights, and intention to fly in the future. Clinical data available from the electronic health records included demographic characteristics, time from T1D diagnosis, glycated hemoglobin (HbA1c) level, current medication, comorbidities, and presence of microalbuminuria. Subjects were also asked to abstain from alcohol and caffeine for at least six hours before the study to reduce the possible autonomic effects and measurement bias.25 Patients with T1D were treated with rapid acting insulin analogues (continuous subcutaneous insulin infusion [CSII]), or long- and rapid-acting insulin analogues (multiple daily injections [MDI]). All volunteers were asked not to eat or take insulin (MDI) or insulin boluses (CSII) in the two hours preceding the study to minimize its vasodilatory effects in the observed vascular response.26 It was also confirmed before the start of the experimental protocol that no diabetic patient had hypoglycemia (<70 mg/dL) or level 1 hyperglycemia (>180 mg/dL). Last, to minimize the effect of diurnal variations in the systemic and ocular measurements, the individuals of each group were evenly distributed among the scheduled morning and afternoon study sessions.

Ophthalmic exclusion criteria for both groups were as follows: the presence of significant lens opacities (Lens Opacities Classification System III equal to or more stage 2), diabetic retinopathy, high refractive error (spherical equivalent below −6.50 or above +4.00 diopters), history of glaucoma or ocular hypertension, neuro-ophthalmic disease, and previous intraocular surgery. Systemic exclusion criteria included the following: hypertension (defined as systolic blood pressure higher than 140 mm Hg or diastolic blood pressure higher than 90 mm Hg), medically treated hypertension, nephropathy or other documented microvascular complications, local or systemic inflammatory diseases, and smokers of more than 20 cigarettes a day. Pregnant women were also excluded.

**Study Protocol**

First, the study protocol was explained individually to every subject, written consent was obtained, and the health questionnaire was completed. Then, all subjects underwent a complete ophthalmological examination including best-corrected visual acuity, slit-lamp biomicroscopy with fundoscopy, autorefraction (RK-5; Canon, Inc., Tokyo, Japan), fundus photography (CR-2; Canon, Inc.), intracocular pressure measurement, and ocular biometry (Lenstar; Haag-Streit Diagnostics, Koniz, Switzerland). Other baseline measurements performed included arterial blood pressure and pulse oximetry (CareScape V100; GE Healthcare, Chicago, IL, USA). Room temperature was maintained at 22°C, and consistent mesopic conditions were maintained throughout the study.

A commercial OCTA device was used (Avanti XR, version 2017.1.0.151; Optovue, Fremont, CA, USA), with an A-scan rate of 70,000 A-Scan/s with 5-mm axial resolution and using a split-spectrum amplitude-decorrelation angiography algorithm, thus giving an enhanced signal-to-noise ratio of flow detection. The device used also included the latest projection artefact removal software, allowing for a more-precise analysis of the deep plexus. All examinations were performed by an experienced technician at the determined timepoints using the 6- x 6-mm standard protocol for macular OCTA examination. Two repeated scans were performed—one at baseline and another during the stress test. Vessel density of the superficial and deep plexuses were assessed from the en face angiograms by analyzing a predefined annulus with an outer diameter of 3 mm and an inner diameter of 1 mm.
corresponding to the parafoveal region. This vessel density value was automatically generated using built-in AngioAnalytics. Only high-quality images (signal strength > 8/10, focused, and without movement artefacts) were included in the analysis. No subjects were excluded as a result of poor imaging quality. However, and of note for future studies, it is worth mentioning that because of the sustained isometric effort required during the handgrip test, a minority of the volunteers found it difficult to keep a completely steady position in the OCTA chinrest. This specific situation affected the imaging mostly with movement artefacts, and the examinations needed to be repeated once in four of the 48 subjects (two in each group).

**Vasodilatory Response—HCT.** The physiological response to hypoxia has been previously reported. Similarly to the cerebral vasculature, retinal vessels respond to a decrease in PaO₂ with vasodilation and increase in blood flow. This local autoregulatory adaptation contributes to keep a rather stable oxygen pressure in the inner retina until PaO₂ levels are as low as 40 mm Hg.²⁻³¹

The following protocol has been described in detail in a previous publication.²¹ Briefly, the HCT is a standard test performed at sea level to create a normobaric hypoxic environment by reducing the FiO₂ and making it equivalent to that of a flight cabin. The parameters monitored during HCT include oxygen peripheral saturation, arterial pressure, and continuous electrocardiography. As established by the British Thoracic Society, the recommended HCT duration to obtain stable conditions is 20 minutes. Accordingly, OCTA was performed at baseline and then again 30 minutes after HCT start (i.e., in plateau hypoxic conditions). All symptoms were recorded, and the test was stopped if medically necessary.

**Vasocostrictive Response—Handgrip Test.** It is known that isometric exercise is used to evaluate sympathetic autonomic response causing steady and safe increases in heart rate and arterial blood pressure, along with physiological peripheral vasoconstriction.²⁴ In the retina, the blood flow remains relatively unchanged until the mean ocular perfusion pressure increases by 35% to 60% above baseline. This is achieved through a local autoregulatory increase in vascular resistance—i.e., retinal vasoconstriction.³²⁻³⁴

The following protocol has been described in detail in a previous publication.²¹ In brief, subjects sit in front of the OCTA device, with the forearm in neutral position, the elbow flexed at approximately 90°, and the wrist with the thumb facing upward. Using a Jamar hydraulic dynamometer, the participant is asked to keep a steady contraction of at least one third of the maximal calculated force. The OCTA acquisition starts in the plateau phase, i.e., after 90 seconds, being completed for both eyes within the 3- to 5-minute test period. The arterial pressure in the contralateral arm is measured every 90 seconds. According to the test recommendations, if a diastolic blood pressure reaches values higher than 120 mm Hg or any adverse symptom is registered, the test is immediately interrupted.

**Primary and Secondary Outcomes**

A comparative analysis for each group—T1D patients and healthy controls—was undertaken for the following outcomes: (1) parafoveal vessel density evaluated using OCTA at baseline and during HCT; (2) parafoveal vessel density evaluated using OCTA at baseline and during the handgrip test; and (3) systemic cardiovascular response in both scenarios.

**Statistics**

Sample size was calculated considering a 5% clinically significant difference in mean vessel density between groups and a standard deviation of 5%. Considering a power of 90%, an alpha value of 0.05, a minimum of 17 TID patients and controls should be included. To account for the attrition rate and to maintain the power of the study, a total of 24 patients were included in each group.

Statistical analysis was performed using STATA v14.1. A repeated-measures analysis of variance (ANOVA) model was used to assess differences between the baseline and stress tests’ measurements. The skewness-kurtosis test was used to assess the normal distribution of the variables considered, and the inexistence of significant outlier values was also confirmed. Equality of variances was investigated, and the results were reported accordingly, applying the Greenhouse-Geisser correction when variables’ variances were not equal.³⁵ A P value <0.05 was considered for statistical significance. To guarantee independent observations, only the right eye of each patient was considered for analysis.

**RESULTS**

**Demographics and Baseline Data**

Forty-eight eyes of 24 healthy subjects and 24 T1D patients without evidence of diabetic retinopathy were studied. In the T1D group, the mean HbA1c value was 7.9% ± 1.4% (range 6.2%–11.5%) and the mean time from the diagnosis was 14.8 ± 9.7 years (range 2–36 years). Both groups were similar with respect to the demographic and baseline characteristics, including age, gender, arterial blood pressure, heart rate, body mass index, ocular axial length, intraocular pressure and best-corrected visual acuity (Table 1). Of note, and as previously reported elsewhere,³⁶⁻³⁷ a baseline rarefraction of the superficial and deep parafoveal plexuses was noted in the group of patients with diabetes, even before clinically evident retinopathy (Table 1).

**Systemic Response**

**Hypoxia Challenge Test.** The median peripheral oxygen hemoglobin saturation decreased from 97% to 88% in both groups (Table 2). Also, as expected, an increase in the heart rate was noted in hypoxic conditions in both groups to increase the cardiac output. The arterial blood pressure changes were less notable, with a mild decrease in mean arterial pressure noted in the control group and no significant differences in T1D patients (Table 2).

**Handgrip Test.** As shown in Table 3, the handgrip test was associated with a significant increase of the heart rate and systolic and diastolic arterial blood pressure in both groups.

**Retinal Vascular Response**

**Hypoxia Challenge Test (Fig. 1).** In the healthy cohort, the median parafoveal vessel density in the superficial plexus increased from 55.1 (53.1–56.4) in baseline conditions to 56.5 (54.0–57.6) in hypoxia (F₁,₁₂ = 15.69, P < 0.001). The median parafoveal vessel density in the deep
Table 1. Demographic and Baseline Data

|                          | Control           | Type 1 Diabetes | P Value |
|--------------------------|-------------------|-----------------|---------|
| Age, mean (SD), years    | 31.8 (8.2)        | 36.9 (10.4)     | 0.07    |
| Male/Female, n           | 10/14             | 10/14           | 1.00    |
| SAP, mean (SD), mm Hg    | 117 (12)          | 117 (9)         | 0.85    |
| DAP, mean (SD), mm Hg    | 78 (9)            | 77 (6)          | 0.13    |
| Heart rate, median (IQR), beats/min | 62 (58–67) | 62 (56–71) | 0.63 |
| Body mass index, mean (SD), kg/m² | 22.6 (3.0) | 25.1 (3.9) | 0.06 |
| Axial length, mean (SD), mm | 24.1 (0.9) | 23.5 (1.0) | 0.07 |
| Intraocular pressure, mean (SD), mm Hg | 13.3 (2.1) | 14.6 (3.0) | 0.14 |
| Visual acuity, median (IQR), logMAR | 0 (0–0) | 0 (0–0) | 0.45 |
| Superficial plexus       | 55.1 (53.1–56.4)  | 53.1 (48.9–55.1)| 0.016 |
| Deep plexus              | 60.4 (59.3–61.8)  | 57.2 (53.3–60.0)| <0.001 |
| HbA1c, mean (SD), %      | —                 | 7.9 (1.4)       | —       |
| Time since diagnosis, mean (SD) | —               | 14.8 ± 9.7     | —       |

P values obtained with Student’s t test, Wilcoxon rank-sum (Mann-Whitney) test or Pearson’s χ² test, as appropriate. DAP, diastolic arterial blood pressure; SAP, systolic arterial blood pressure; SD, standard deviation; IQR, interquartile range.

Table 2. Systemic Response to the Hypoxia Challenge Test

|                          | Control           | P Value | Type 1 Diabetes | P Value |
|--------------------------|-------------------|---------|-----------------|---------|
| O₂ Hb saturation, median (IQR), % | | | | |
| Baseline                 | 97 (97–98)        | —       | 97 (97–98)      | —       |
| Hypoxia                  | 88 (85–89)        | <0.0001 | 88 (86–89)      | <0.001  |
| SAP, mean (SD), mm Hg    | 117 (12)          | —       | 117 (9)         | —       |
| Hypoxia                  | 114 (10)          | 0.05    | 118 (11)        | 0.25    |
| DAP, mean (SD), mm Hg    | 78 (9)            | —       | 77 (6)          | —       |
| Hypoxia                  | 75 (10)           | 0.045   | 75 (7)          | 0.10    |
| MAP, mean (SD), mm Hg    | 91 (10)           | —       | 90 (6)          | —       |
| Hypoxia                  | 88 (9)            | 0.02    | 89 (8)          | 0.40    |
| Heart rate, median (IQR), beats/min | 62 (58–67) | —       | 62 (56–71)     | —       |
| Hypoxia                  | 74 (71–80)        | <0.001  | 79 (65–86)      | <0.001  |

P values (versus baseline) obtained with Student’s t test and Wilcoxon rank-sum (Mann-Whitney) test, as appropriate. DAP, diastolic arterial pressure; Hb, hemoglobin; MAP, mean arterial blood pressure; SAP, systolic arterial pressure; SD, standard deviation; IQR, interquartile range.

In the T1D group, there were no statistically significant differences during hypoxia for the superficial (F₁,₂₃ = 0.06, P = 0.81) or deep (F₁,₂₃ = 1.08, P = 0.31) parafoveal plexuses.

Handgrip Test (Fig. 2). In the control group, isometric exercise elicited a significant decrease in vessel density in both superficial (55.8 [53.5–56.9] to 54.1 [52.2–54.5]) and parafoveal plexuses.

Table 3. Systemic Response to the Handgrip Test

|                          | Control           | P Value | Type 1 Diabetes | P Value |
|--------------------------|-------------------|---------|-----------------|---------|
| SAP, mean (SD), mm Hg    | 118 (11)          | —       | 123 (12)        | —       |
| Handgrip                 | 150 (18)          | <0.0001 | 155 (24)        | <0.0001 |
| DAP, mean (SD), mm Hg    | 75 (9)            | —       | 79 (9)          | —       |
| Handgrip                 | 102 (14)          | <0.0001 | 98 (13)         | <0.0001 |
| MAP, mean (SD), mm Hg    | 89 (9)            | —       | 94 (9)          | —       |
| Handgrip                 | 123 (13)          | <0.0001 | 122 (17)        | <0.0001 |
| Heart rate, median (IQR), beats/min | 67 (64–73) | —       | 62 (67–78)     | —       |
| Handgrip                 | 77 (71–85)        | <0.01   | 79 (68–87)      | <0.01   |

P values (versus baseline) obtained with Student’s t test and Wilcoxon rank-sum (Mann-Whitney) test, as appropriate. DAP, diastolic arterial pressure; MAP, mean arterial blood pressure; SAP, systolic arterial pressure; SD, standard deviation; IQR, interquartile range.
FIGURE 1. Exemplar of the setup during the hypoxia challenge test and OCT-angiography examination (A, B) and macular en-face 6×6-mm angiograms obtained in baseline conditions (C) and during the hypoxic test (D). The angiograms belong to the healthy volunteer depicted in B. Vessel density increased in hypoxic conditions as expected. Image quality score and parafoveal vessel density are provided according to the built-in angioanalytics software, as described in the Methods section.

TABLE 4. Retinal Vascular Response to the Hypoxia Challenge Test

| Parafoveal Vessel Density, Median (IQR) | Control | P Value | Type 1 Diabetes | P Value |
|----------------------------------------|---------|---------|-----------------|---------|
| Superficial plexus                     |         |         |                 |         |
| Baseline                               | 55.1 (53.1–56.4) | — | 53.1 (48.9–55.1) | — |
| Hypoxia                                | 56.5 (54.0–57.6) | <0.001 | 52.0 (50.0–54.2) | 0.81 |
| Deep plexus                            |         |         |                 |         |
| Baseline                               | 60.4 (59.3–61.8) | — | 57.2 (53.3–60.0) | — |
| Hypoxia                                | 62.0 (59.9–62.8) | < 0.001 | 56.2 (54.4–57.9) | 0.31 |

P values (versus baseline) obtained with ANOVA repeated-measures. IQR, interquartile range.

FIGURE 2. Exemplar of the setup during the handgrip test and OCT-angiography examination (A) and macular en-face 6×6-mm angiograms obtained in baseline conditions (B) and during the handgrip test (C). The angiograms belong to a volunteer with type 1 diabetes with no clinical evidence of diabetic retinopathy. The physiological decrease in vessel density during the handgrip test was not observed. Image quality score and parafoveal vessel density are provided according to the built-in angioanalytics software, as described in the Methods section.
OCTA is an innovative, noninvasive, and safe technology that is increasingly available in clinical practices worldwide and may be further optimized for this purpose. The ability to evaluate individual functional responses has multiple potential advantages. First, it overcomes the limitations of interpreting single structural exams that may vary among patients, including predetermined OCTA metrics, such as the foveal avascular zone.54 Additionally, the retinal functional response may be a more sensitive marker to detect earlier changes, when compared with a structurally normal OCT scan or fluorescein angiography. This may well have potential implications when considering monitoring and managing the metabolic, systemic and ophthalmic manifestations of the disease.42 We found a significantly altered vascular response in subjects with type 1 diabetes before any clinical evidence of diabetic retinopathy. This abnormal retinal microvascular response may correspond to an earlier marker of endothelial dysfunction or changes in the signaling between the retina and the vessels (i.e., neurovascular coupling),27,45,44 and we provide a novel way of studying it noninvasively using modern OCTA technology.

Another interesting finding of our study is the notion that the cardiovascular systemic response does not appear to be significantly different between the groups. The circumstantial finding of a statistically significant decrease in the arterial blood pressure of the healthy cohort during mild hypoxia (which was not clearly observed in the diabetic group) seems to have limited clinical meaning. However, this may be worth clarifying in future studies. The identified abnormal regional retinal response suggests there is an increased ability of OCTA to sensitively identify vascular changes. As an innovative, noninvasive, and safe technology, able to study a central nervous system (i.e., retinal) microvasculature, OCTA is also becoming a useful tool for the study of nonophthalmic conditions. Multiple reports have been published with OCTA applications mainly in neurodegenerative conditions (e.g., Parkinson, Alzheimer’s, multiple sclerosis), but also in other diseases.45–52 Therefore studying a patient's retinal vascular responses can be a useful adjunct to routine structural anatomical evaluation with interesting application also in other medical specialities. This study highlights the potential to adapt the available OCTA technology to combine this form of functional analysis to the currently available structural angiogram.

With this study, we have demonstrated an attenuated retinal vascular response in patients with type 1 diabetes with no clinical evidence of ocular disease. However, these findings should be interpreted along with the limitations of our study. Although well-powered for the main outcomes, the young age group, Caucasian population and relatively small sample size may limit the external validity of the study and also the possibility of multivariate analysis with certain demographics and subgroup features. Also, the diurnal changes of the systemic and ocular variable analyzed were minimized as possible but should not be excluded as a potential source of bias. Despite careful recruitment, the wide range of diabetes’ duration in our sample may suggest the underestimation of the diabetic retinopathy status, because some patients would be above the usual time for the early manifestations of DR (such as peripheral hemorrhages, microaneurysms, or both),53 that could have been underreported with our methodology. Larger studies, including patients with a range of disease severity through

### Table 5. Retinal Vascular Response to the Handgrip Test

| Parfoveal Vessel Density, Median (IQR) | Control | Type 1 Diabetes | P Value | P Value |
|----------------------------------------|---------|-----------------|---------|---------|
| **Superficial plexus**                 |         |                 |         |         |
| Baseline                               | 55.8 (53.5–56.9) | —             | 53.5 (51.1–55.4) | —       |
| Handgrip                               | 54.1 (52.2–54.5) | <0.0001       | 52.8 (48.7–54.8) | 0.06    |
| **Deep plexus**                        |         |                 |         |         |
| Baseline                               | 60.4 (58.7–61.2) | —             | 58.5 (54.1–60.3) |         |
| Handgrip                               | 57.1 (53.7–58.6) | <0.0001       | 55.9 (52.5–60.3) | <0.01   |

P values (versus baseline) obtained with ANOVA repeated-measures. IQR, interquartile range.
the various ETDRS levels would be useful to add weight to our findings. Second, although individuals with type 1 diabetes were selected to minimize the influence of any co-pathologies and systemic medication in the vascular analysis, a small number of subjects were under systemic medication (other than insulin): four patients were on levothyroxine, two were on simvastatin, one patient was taking sertraline, and one patient was on mexazolam and levothyroxine. The patients taking levothyroxine had normal thyroid function test results. Although unlikely to affect the observed patterns of retinal vascular response, we acknowledge the potential vascular effects of these drugs. 

Likewise, current blood glucose concentration itself may have a significant vascular effect. Because this parameter was not systematically evaluated in both groups, it is also a limitation of our study protocol that we were not able to rigorously control the observed vascular response for the current glycemia. Third, although widely used in clinics and research, the OCTA technology is not yet optimized for these functional analyses, and it should be remembered that this technology measures perfused vessel densities, not absolute blood flows. Last, to ensure that the protocol for dynamic retinal microvasculature analysis is as reproducible as possible, we used the manufacturer’s default software for superficial and deep capillaryplexuses analysis. Thus the inherent bias related to segmentation and differences to other devices and models should be considered. We are certain that this study acts as a valuable contributor to the development of the OCTA technology as a realistic tool in functional retinal analysis.

In conclusion, we used OCTA technology in conjunction with standardized stress tests and observed an early impairment in the physiological retinal vascular response in patients with type 1 diabetes before any clinical evidence of retinopathy. Further work is required to better delineate the process of DR development and to develop tools that optimize its clinical significance.

Acknowledgments

The authors thank the Faculty of Medicine and the University of Lisbon, as well as the technicians involved in the study: Diana Francisco, Sofia Silva, and Telma Gala. The authors also thank J. L. Ducla-Soares and the Autonomic Nervous System Department of Lisbon Academic Medical Center for all the support, as well as José Cotta Ems Lda for providing the necessary equipment and logistical backing for the study. And last, the authors appreciate the help with spelling and grammar revision provided by and logistical backing for the study. And last, the authors appreciate the help with spelling and grammar revision provided by Andrew Walkden (University of Manchester, Manchester, UK).

Disclosure: D.C. Sousa, None; I. Leal, None; S. Moreira, None; S. do Vale, None; A.S. Silva-Herda, None; P. Aguiar, None; P. Dionisio, None; L. Abegão Pinto, None; M.A.R.B. Castanho, None; C. Marques-Neves, None.

References

1. Nentwich MM, Ulbig MW. Diabetic retinopathy—ocular complications of diabetes mellitus. World J Diabetes. 2015;6:489–499.

2. Leasher JL, Bourne RRA, Flaxman SR, et al. Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 1990 to 2010. Diabetes Care. 2016;39:1643–1649.

3. Tavares Ferreira J, Proença R, Alves M, et al. Retina and Choroid of Diabetic Patients Without Observed Retinal Vascular Changes: A Longitudinal Study. Am J Ophthalmol. 2017;176:15–25.

4. Safi H, Safi S, Hafezi-Moghadam A, Ahmadieh H. Early detection of diabetic retinopathy. Surv Ophthalmol. 2018;63:601–608.

5. Lasta M, Pemp B, Schmidl D, et al. Neurovascular dysfunction precedes neural dysfunction in the retina of patients with type 1 diabetes. Invest Ophthalmol Vis Sci. 2013;54:842–847.

6. Trick GL, Edwards P, Desai U, Berkowitz BA. Early supernormal retinal oxygenation response in patients with diabetes. Invest Ophthalmol Vis Sci. 2006;47:1612–1619.

7. Tecilazich F, Feke GT, Mazzantini S, Sobrin L, Lorenzi M. Defective myogenic response of retinal vessels is associated with accelerated onset of retinopathy in type 1 diabetic individuals. Invest Ophthalmol Vis Sci. 2016;57:1523–1529.

8. Lim LS, Leng IH, Ong PG, Foulds W, Shyong Tai E, Wong TY. Dynamic responses in retinal vessel caliber with flicker light stimulation and risk of diabetic retinopathy and its progression. Invest Ophthalmol Vis Sci. 2017;58:2449–2455.

9. Zeng Y, Cao D, Yu H, et al. Early retinal neurovascular impairment in patients with diabetes without clinically detectable retinopathy. Br J Ophthalmol. 2019;103:1747–1752.

10. Koustenis A, Harris A, Gross J, Januleviciene I, Shah A, Siesky B. Optical coherence tomography angiography: An overview of the technology and an assessment of applications for clinical research. Br J Ophthalmol. 2017;101:16–20.

11. Spaide RF, Fujimoto JG, Waheed NK, Sarda SR, Staurenghi G. Optical coherence tomography angiography. Prog Retin Eye Res. 2018;64:1–55.

12. Wei X, Balne PK, Meissner KE, Barathi VA, Schmetterer L, Agrawal R. Assessment of flow dynamics in retinal and choroidal microcirculation. Surv Ophthalmol. 2018;63:646–664.

13. Garrity ST, Iafe NA, Phakulijiwatana N, Chen X, Sarraf D. Quantitative analysis of three distinct retinal capillaryplexuses in healthy eyes using optical coherence tomography angiography. Invest Ophthalmol Vis Sci. 2017;58:5548–5555.

14. Sadda SVR. Defining the role of OCT angiography in clinical practice. Ophthalmol Retin. 2017;1:261–262.

15. Sousa DC, Leal I, Moreira S, et al. Optical coherence tomographyangiography study of the retinal vascular plexuses in type 1 diabetes without retinopathy. Eye. 2020;34:307–311.

16. Carnevali A, Sacconi R, Corbelli E, et al. Optical coherence tomography angiography analysis of retinal vascularplexuses and choriocapillaris in patients with type 1 diabetes without diabetic retinopathy. Acta Diabetol. 2017;54:695–702.

17. Sacconi R, Casaluci M, Borrelli E, et al. Multimodal imaging assessment of vascular and neurodegenerative retinal alterations in type 1 diabetic patients without fundoscopic signs of diabetic retinopathy. J Clin Med. 2019;8:1409.

18. De Carlo TE, Chin AT, Bonini Filho MA, et al. Detection of microvascular changes in eyes of patients with diabetes but not clinical diabetic retinopathy using optical coherence tomography angiography. Retina. 2015;35:2364–2370.

19. Dimitrova G, Chihara E, Takahashi H, Amano H, Okazaki K. Quantitative retinal optical coherence tomography
angiography in patients with diabetes without diabetic retinopathy. *Investig Ophthalmol Vis Sci*. 2017;58:190–196.
20. Durbin MK, An L, Shemonski ND, et al. Quantification of retinal microvascular density in optical coherence tomographic angiography images in diabetic retinopathy. *JAMA Ophthalmol*. 2017;135:370–376.
21. Sousa DC, Leal I, Moreira S, et al. A protocol to evaluate retinal vascular response using optical coherence tomographic angiography. *Front Neurosci*. 2019;13:566.
22. Carlson R V, Boyd KM, Webb DJ. The revision of the Declaration of Helsinki: Past, present and future. *Br J Clin Pharmacol*. 2004;57:695–713.
23. Vohra KP, Klocke RA. Detection and correction of hypoxemia associated with air travel. *Am Rev Respir Dis*. 1993;148:1215–1219.
24. Ewing D, et al. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. *Ewing D, Martyn CJ et al. 1985;8:491–499.
25. Vinader-Caerols C, Monleón S, Carrasco C, Parra A. Effects of alcohol, coffee, and tobacco, alone or in combination, on physiological parameters and anxiety in a young population. *J Caffeine Res*. 2012;2:70–76.
26. Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. *Endocr Rev*. 2007;28:463–491.
27. Pournaras CJ, Rungger-Brändle E, Riva CE, Hardshaw SH, Stefansson E. Regulation of retinal blood flow in health and disease. *Prog Retin Eye Res*. 2008;27:284–350.
28. Cheng RW, Yusof F, Tsui E, et al. Relationship between retinal blood flow and arterial oxygen. *J Physiol*. 2016;594:625–640.
29. Sousa DC, Leal I, Moreira S, Dionísio P, Abegón Pinto L, Marques-Neves C. Hypoxia challenge test and retinal circulation changes—a study using ocular coherence tomography angiography. *Acta Ophthalmol*. 2018;96:e315–e319.
30. Ahmed J, Pulfer MK, Linsenmeier RA. Measurement of blood flow through the retinal circulation of the cat during normoxia and hypoxemia using fluorosence microspheres. *Microvasc Res*. 2001;62:143–153.
31. Steffanson E, Olafs dottedt OB, Elias dottedt TS, et al. Retinal oxymetry: Metabolic imaging for diseases of the retina and brain. *Prog Retin Eye Res*. 2019;70:1–22.
32. Robinson F, Riva CE, Grunwald JE, Petrig BL, Sinclair SH. Retinal blood flow autoregulation in response to an acute increase in blood pressure. *Invest Ophthalmol Vis Sci*. 1986;27:722–726.
33. Blum M, Bachmann K, Wintzer D, Riemer T, Vilser W, Strobel J. Noninvasive measurement of the Bayliss effect in retinal autoregulation. *Graefe's Arch Clin Exp Ophthalmol*. 1999;237:296–300.
34. Zhang Y, Eme etero Nateras OS, Peng Q, Rosende CA, Duong TQ. Blood flow MRI of the human retina/choroid during rest and isometric exercise. *Investig Ophthalmol Vis Sci*. 2012;53:4299–4305.
35. Abdi H. The greenhouse-gisser correction. *Encycl Res Des Sage Publ*. 2010;95:e751–e755.
36. Li T, Jia Y, Wang S, et al. Retinal Microvascular Abnormalities in Children with Type 1 Diabetes Mellitus Without Visual Impairment or Diabetic Retinopathy. *Investig Ophthalmol Vis Sci*. 2019;60:990–998.
37. Simonett JM, Scarinci F, Picconi F, et al. Early microvascular retinal changes in optical coherence tomography angiography in patients with type 1 diabetes mellitus. *Acta Ophthalmol*. 2017;95:e751–e755.
38. Song SH. Complication characteristics between young-onset type 2 versus type 1 diabetes in a UK population. *BMJ Open Diabetes Res Care*. 2015;3:e000044.
39. Cao D, Yang D, Huang Z, et al. Optical coherence tomography angiography discerns preclinical diabetic retinopathy in eyes of patients with type 2 diabetes without clinical diabetic retinopathy. *Acta Diabetol*. 2018;55:469–477.
40. Safi H, Safi S, Hafezi-Moghadam A, Ahmadieh H. Early detection of diabetic retinopathy. *Surv Ophthalmol*. 2018;63:601–608.
41. Kaizu Y, Nakao S, Arima M, et al. Flow density in optical coherence tomography angiography is useful for retinopathy diagnosis in diabetic patients. *Sci Rep*. 2019;9:1–7.
42. Sun Z, Tang F, Wong R, et al. OCT angiography metrics predict progression of diabetic retinopathy and development of diabetic macular edema: a prospective study. *Ophthalmology*. 2019;126:1675–1684.
43. Justesen BL, Mistry P, Chaturvedi N, et al. Retinal arterioles have impaired reactivity to hyperoxia in type 1 diabetes. *Acta Ophthalmol*. 2010;88:453–457.
44. Ashimatey BS, Green KM, Chu Z, Wang RK, Kashani AH. Impaired retinal vascular reactivity in diabetic retinopathy as assessed by optical coherence tomography angiography. *Investig Ophthalmol Vis Sci*. 2019;60:2468–2473.
45. Kwapong WR, Ye H, Peng C, et al. Retinal microvascular impairment in the early stages of Parkinson's disease. *Investig Ophthalmol Vis Sci*. 2018;59:4115–4122.
46. Kim SV, Semoun O, Pedinielli A, Jung C, Miere A, Souied EH. Optical coherence tomography angiography quantitative assessment of exercise-induced variations in retinal vascular plexa of healthy subjects. *Investig Ophthalmol Vis Sci*. 2019;60:1412–1419.
47. O’Byrhim BE, Apte RS, Kung N, Coble D, Van Stavern GP. Association of preclinical Alzheimer disease with optical coherence tomographic angiography findings. *JAMA Ophthalmol*. 2018;136:1242–1248.
48. Feucht N, Maier M, Lepennetier G, et al. Optical coherence tomography angiography indicates associations of the retinal vascular network and disease activity in multiple sclerosis. *Mult Scler J*. 2019;25:224–234.
49. DeBuc DC, Somfai GM, Koller A. Retinal microvascular network alterations: potential biomarkers of cerebrovascular and neural diseases. *Am J Physiol Heart Circ Physiol*. 2017;312:H201–H212.
50. Vasudevan S, Vo J, Shafer B, Nam AS, Yakoc BJ, Hammer DX. Toward optical coherence tomography angiography-based biomarkers to assess the safety of peripheral nerve electrostimulation. *J Neural Eng*. 2019;16:036024.
51. Zhang YS, Zhou N, Knoll BM, et al. Parafoveal vessel loss and correlation between peripapillary vessel density and cognitive performance in amnestic mild cognitive impairment and early Alzheimer's Disease on optical coherence tomography angiography. *PloS One*. 2019;14:e0214685.
52. Zhang L, Li M, Liu Y, Zhou Q. Combining optical coherence tomography with magnetic resonance angiography and Doppler ultrasonography for clinical detection of scleroderma. *Anat Rec*. 2019, doi:10.1002/ar.24340.
53. Thomas RL, Dunstan FD, Luzio SD, et al. Prevalence of diabetic retinopathy within a national diabetic retinopathy screening service. *Br J Ophthalmol*. 2015;99:64–68.
54. Colussi GL, Di Fabio A, Catena C, Chiuch A, Sechi LA. Involvement of endothelium-dependent and-independent mechanisms in midazolam-induced vasodilation. *Hypertens Res*. 2011;34:929–934.
55. Lefer AM, Scalia R, Lefer DJ. Vascular effects of HMGC reductase inhibitors (statins) unrelated to cholesterol lowering: New concepts for cardiovascular disease. *Cardiovasc Res*. 2001;49:281–287.
56. Pizzi C, Mancini S, Angeloni L, Fontana F, Manzoli L, Costa GM. Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. *Clin Pharmacol Ther*. 2009;86:527–532.

57. Carrillo-Sepúlveda MA, Ceravolo GS, Fortes ZB, et al. Thyroid hormone stimulates NO production via activation of the PI3K/Akt pathway in vascular myocytes. *Cardiovasc Res*. 2010;85:560–570.

58. Nowaczewska M, Kamińska A, Kukulska-Pawluczuk B, Junik R, Pawlak-Osínska K. Effect of hyperglycemia on cerebral blood flow in patients with diabetes. *Diabetes Res Clin Pract*. 2019;153:1–5.

59. Luksch A, Lasta M, Polak K, et al. Twelve-hour reproducibility of retinal and optic nerve blood flow parameters in healthy individuals. *Acta Ophthalmol*. 2009;87:875–880.